Author

M. K. Morris

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Biochemistry· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 2 Organism:non-human primate· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Hanson· 3 shared A. Rustagi· 2 shared C. J. Miller· 2 shared J. Do· 2 shared L. Fritts· 2 shared M. Sanyal· 2 shared N. Friedland· 2 shared P. S. Kim· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

C. Hanson

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Administration of vaccine-boosted COVID-19 convalescent plasma to SARS-CoV-2 infected hamsters decreases virus replication in lungs and hastens resolution of the infection despite transiently enhancing disease and lung pathology.

T. Carroll, T. Wong, M. K. Morris, C. Di Germanio, Z.-M. Ma, M. Stone, E. E. Ball, L. Fritts, A. Rustagi, G. Simmons, M. P. Busch, C. J. Miller

This study shows that vaccine-boosted convalescent plasma reduces SARS-CoV-2 replication in hamsters but temporarily worsens disease and lung pathology.

bioRxiv · Aug 22, 2023 · PreprintImmunology

Decreased efficacy of a COVID-19 vaccine due to mutations present in early SARS-CoV-2 variants of concern

P. A. Weidenbacher, N. Friedland, M. Sanyal, M. K. Morris, J. Do, C. Hanson, P. S. Kim

This study evaluates the efficacy of a pan-sarbecovirus vaccine candidate against SARS-CoV-2 variants, finding that omitting strain-specific mutations improves cross-reactive neutralizing antibody responses.

bioRxiv · Jun 27, 2023 · PreprintBiochemistry

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

P. A.- B. Weidenbacher, M. Sanyal, N. Friedland, S. Tang, P. S Arunachalam, M. Hu, O. S. Kumru, M. K. Morris, J. Fontenot, L. Shirreff, J. Do, Y.-C. Cheng, G. Vasudevan, M. B. Feinberg, F. J. Villinger, , P. S. Kim

This paper describes a ferritin-based nanoparticle vaccine, DCFHP-alum, that induces strong, long-lasting neutralizing antibodies against SARS-CoV-2 variants in non-human primates.

bioRxiv · Dec 25, 2022Immunology

The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters

T. Carroll, D. Fox, N. van Doremalen, E. Ball, M. K. Morris, A. Sotomayor-Gonzalez, V. Servellita, A. Rustagi, C. K. Yinda, L. Fritts, J. R. Port, Z.-M. Ma, M. Holbrook, J. Schulz, C. A. Blish, , C. J. Miller

This study shows that the B.1.427/1.429 (epsilon) SARS-CoV-2 variants cause more severe disease and higher viral loads in the upper respiratory tract in Syrian hamsters compared to the ancestral B.1 (614G) strain.

bioRxiv · Aug 25, 2021Microbiology